There are currently 57 clinical trials in Tamarac, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including GSK Investigational Site, West Broward Rheumatology Associates, Inc., Novartis investigative site and Phoenix Clinical Research, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
Recruiting
The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjogrens syndrome who have previously completed treatment from one of two NEPTUNUS 1 year core studies (CVAY736A2301 \[NCT05350072\] or CVAY736A2302 \[NCT05349214\]). * The study treatment is ianalumab 300 mg in a 2 mL pre-filled syringe (PFS) or in a 2 mL autoinjector (AI) for injection. All participants will receive ianalumab either monthly or every 3 months. * The treatment duratio... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2025
Locations: West Broward Rheumatology Associates Inc, Tamarac, Florida
Conditions: Sjogrens Syndrome
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2025
Locations: Dh Tamarac Research Center Etna Medical Center Emc, Tamarac, Florida
Conditions: Prurigo Nodularis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Recruiting
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
03/28/2025
Locations: Dh Tamarac Research Center Etna Medical Center Emc, Tamarac, Florida
Conditions: NonSegmental Vitiligo
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
Recruiting
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythematosus (SLE). The extension period will provide additional long-term safety and efficacy data and enable those participants initially randomized to placebo to receive treatment with Afimetoran.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/28/2025
Locations: West Broward Rheumatology Associates, Tamarac, Florida
Conditions: Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS. 2. To evaluate the safety and tolerability of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: West Broward Rheumatology Associates, Inc., Tamarac, Florida
Conditions: Sjogren's Syndrome
A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on patient-reported symptoms of SS in participants with moderate-to-severe symptom state Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient-reported outcomes (PROs) in participants with SS. 2. To evaluate the effect of dazodalibep on measures of systemic activity, PROs, and salivary flow in participants with SS 3. To evaluate the safety and tolerability of multiple doses of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: West Broward Rheumatology Associates, Inc., Tamarac, Florida
Conditions: Sjögren's Syndrome (SS)
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Recruiting
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/26/2025
Locations: BRCR Medical Center Inc., Tamarac, Florida
Conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-nul... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
03/25/2025
Locations: Boca Raton Clinical Research Medical Center Inc, Tamarac, Florida
Conditions: Advanced MTAP-null Solid Tumors
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Recruiting
The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Advanced Research, Tamarac, Florida
Conditions: Myelodysplastic Syndromes
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
03/24/2025
Locations: D&H Tamarac Research Center LLC, Tamarac, Florida
Conditions: Migraine
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
Recruiting
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associate... Read More
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
03/24/2025
Locations: D&H Tamarac Research Center /ID# 250434, Tamarac, Florida
Conditions: Depression, Bipolar I Disorder
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/22/2025
Locations: TBC Research, Tamarac, Florida
Conditions: Hypertriglyceridemia